| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| AtheroGenics, Inc |
| 8995 Westside Parkway, Alpharetta, GA 30004 * (678) 336-2500 |
| Business Description | The company is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. |
| Offering Information Company has | |||
| Trading As | AGIX (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 2/25/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 8/8/00 |
| Foreign Shares Offered | 0 | Filing Range | $11.00 - $13.00 |
| Company Shares | 6,000,000 | Offer Price | $8.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.560 |
| Gross Proceeds | $48,000,000 | Selling | $0.330 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 22,820,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| A.G. Edwards & Sons, Inc. | Co-manager | (314) 955-3039 |
| Adams, Harkness & Hill | Co-manager | (617) 371-3705 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 0.000 | 0.000 | 5.792 | - | - |
| Income from Oper. | - | - | -5.645 | -10.528 | -5.928 | - | - |
| Net Income | - | - | -5.159 | -10.734 | -5.989 | - | - |
| E.P.S | - | - | -2.250 | -4.450 | -2.450 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -6.68 | - | - | ||||
| Cash Flow - Inv. | -1.12 | - | - | ||||
| Cash Flow - Fin. | 17.52 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 15.72 | Current Assets | 14.29 | Current Ratio | 10.94 |
| Total Liab. | 40.56 | Current Liab. | 1.31 | Debt Ratio | 258.07% |
| Total Equity | -24.84 | Working Cap. | 12.98 | Debt to Equity Ratio | - |
| Cash | 13.41 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used research and development activities, including clinical trials, process development and manufacturing support, potential licensing and acquisition opportunities and for general corporate purposes including working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Long, Aldridge & Norman |
| Bank's Law Firm | Brown & Wood |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Alliance Technology Ventures LP | 16.80 | |
| William Blair Capital Partners VI, L.P. | 16.50 | |
| Entities affiliated with Sprout Capital, VII, L.P. | 10.50 | |
| Entities affiliated with Domain Associates, L.L.C. | 10.20 | |
| Note: represents ownership of 5% or more prior to the offering. | ||